Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Dermatology

Modern Management: Treating the PASH Triad

At a Glance

PASH syndrome has no single FDA-approved treatment, so care is usually personalized and combines medicines for active pyoderma gangrenosum, severe acne, and hidradenitis suppurativa. Biologics, infection screening, laboratory tests, and careful timing of surgery help manage flares and treatment risks.

Because PASH syndrome is a complex “triad” of three different conditions, there is no single FDA-approved “PASH pill” [1]. Instead, your medical team will create a multimodal treatment plan, often using medications off-label, based on evidence from small series, case reports, or guidelines for the individual components [2][3].

Rapid Control: Systemic Therapies

When you are experiencing an active flare of Pyoderma Gangrenosum (PG), the first goal is to stop the rapid tissue destruction. Doctors often turn to fast-acting systemic medications to cool down the inflammation [4].

  • Systemic Corticosteroids: Drugs like prednisone or methylprednisolone are often the first line of defense. They work very quickly to suppress the immune system, but because of long-term side effects (like bone loss and weight gain), they are usually tapered down as soon as the ulcers begin to heal [5][6].
  • Cyclosporine: This is a powerful immunosuppressant that can be highly effective for PG. It acts quickly but requires close monitoring of your blood pressure and kidney function [4][7].

Long-Term Management: Biologic Therapies

Depending on your symptoms, your doctor may incorporate biologics into your long-term plan. These are engineered proteins that target specific parts of the immune system “alarm” system. For PASH, they are generally used off-label [1][8].

  • TNF-alpha Inhibitors: Medications like adalimumab and infliximab are frequently used for PASH [1]. Infliximab, which is given via IV infusion, has shown improvement in some cases in small studies that did not respond to other therapies [9].
  • IL-1 Inhibitors: Because PASH is an autoinflammatory disease involving a protein called Interleukin-1 (IL-1), drugs like anakinra or canakinumab may be used [2]. These are often considered if TNF inhibitors do not work [10][11].
  • IL-17 Inhibitors: Emerging research suggests that medications like secukinumab may help some patients with PASH-spectrum symptoms, though they must be used with caution in patients who also have inflammatory bowel disease (IBD) [12][13].

Targeted Acne Management

The acne in PASH is typically severe and nodulocystic, meaning standard topical creams are rarely enough [14]. Many patients consider isotretinoin (commonly known as Accutane) to prevent permanent scarring [15]. Because isotretinoin can cause severe birth defects (teratogenicity), you must participate in strict pregnancy-prevention programs if you are of childbearing potential. It also requires careful monitoring of liver function, lipid levels, and mood. Because of the complexity of PASH, isotretinoin is sometimes used alongside biologics, requiring careful specialist coordination [14][9].

The Role of Antibiotics and Surgery

While PASH is autoinflammatory, antibiotics are often included in your treatment plan for their anti-inflammatory properties or to treat secondary infections [1].

  • Combination Therapy: Doctors may use combinations like clindamycin and rifampin, which are standard for Hidradenitis Suppurativa (HS). However, this combination carries risks of C. difficile infection, severe drug interactions, and hepatotoxicity, limiting how long it can safely be used [16].
  • Surgery: If HS has created deep tunnels or “sinus tracts,” surgery may be necessary to remove them. However, surgery in PASH patients carries the risk of pathergy (new ulcers forming at the surgical site). For this reason, elective surgery is usually only performed when your inflammation is well-controlled by medications [17][1].

Risks and Monitoring

Taking medications that suppress your immune system requires a high level of vigilance. You and your care team will need to monitor several factors:

  1. Infection Risk: Because these drugs lower your defenses, you are at a higher risk for infections. You should have a plan for what to do if you develop a fever or signs of illness [3][18].
  2. Screening: Before starting a biologic, you must be screened for “latent” infections like Tuberculosis (TB) and Hepatitis B, which could reactivate if your immune system is suppressed [3].
  3. Laboratory Tests: Regular blood work is essential to check your white blood cell counts, liver enzymes, and kidney function, depending on which drugs you are taking [3][7].
  4. Skin Cancer Surveillance: Chronic inflammation from HS is associated with a slightly higher risk of a type of skin cancer called squamous cell carcinoma. Any new, rapidly enlarging, or non-healing lesion needs prompt specialist assessment, in addition to regular skin checks [3][19].

Treatment for PASH is often a “marathon,” requiring adjustments over time to find the right balance for your unique biology [16].

Common questions in this guide

What treatments can quickly control a PASH flare?
During an active pyoderma gangrenosum flare, doctors may use systemic corticosteroids such as prednisone or methylprednisolone, or cyclosporine, to suppress inflammation quickly. These medicines require monitoring and are often adjusted or tapered as the flare improves.
Are biologic medicines used for PASH syndrome?
Yes. Biologics such as adalimumab or infliximab may target tumor necrosis factor, while anakinra or canakinumab target interleukin-1; secukinumab is an emerging interleukin-17 option. They are generally used off-label, and selection depends on which PASH features are active, previous treatment response, and conditions such as inflammatory bowel disease.
Can isotretinoin be combined with a biologic for PASH-related acne?
Sometimes, doctors use isotretinoin for severe nodulocystic acne alongside a biologic, but this requires close coordination among specialists. Isotretinoin requires strict pregnancy-prevention measures when applicable and monitoring of liver function, lipid levels, and mood.
What screening is needed before starting a PASH biologic?
Before a biologic, patients should be screened for inactive or latent tuberculosis and hepatitis B because these infections can reactivate when the immune system is suppressed. Ongoing blood tests may also check blood cell counts, liver enzymes, and kidney function, depending on the medicines used.
Is surgery safe for hidradenitis tunnels in PASH?
Surgery may be needed for deep hidradenitis suppurativa tunnels or sinus tracts, but procedures can trigger pathergy, meaning new ulcers form at the treatment site. Elective surgery is generally considered after inflammation is controlled, with the surgical and medical teams coordinating medication changes.
What should I monitor while taking immune-suppressing PASH medicines?
Tell your care team promptly about fever or other signs of infection, since immune-suppressing medicines can lower your defenses. Monitoring may include blood pressure and kidney tests with cyclosporine, regular blood work, and skin checks for new, rapidly enlarging, or non-healing lesions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of my three conditions (PG, acne, or HS) are we prioritizing for rapid control right now?
  2. 2.Is my current kidney function and blood pressure stable enough for us to use cyclosporine if needed?
  3. 3.Why did you choose this specific biologic (e.g., a TNF inhibitor vs. an IL-1 inhibitor) for my initial treatment?
  4. 4.Can we safely add isotretinoin to my biologic therapy to address my cystic acne, and what extra monitoring will that require?
  5. 5.What is our long-term plan for 'maintenance' therapy once my current flare is under control?
  6. 6.If I need surgery or a procedure for my HS tunnels, how will we coordinate my immunosuppressants to prevent a PG flare?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management.

    Yan A, Gallardo M, Savu A, Kaffenberger B

    Archives of dermatological research 2024; (316(7)):397 doi:10.1007/s00403-024-03125-7.

    PMID: 38878169
  2. 2

    Autoinflammatory Syndromes of Hidradenitis Suppurativa: Updates in Clinical Features, Emerging Associations, and Management.

    Ho JY, Liang AL, Maronese CA, et al.

    Current rheumatology reports 2026; (28(1)).

    PMID: 42593626
  3. 3

    Management of Hidradenitis Suppurativa in Special Populations: A Narrative Review.

    Mallela T, Passannante L, Patel H, et al.

    Dermatology and therapy 2025; (15(8)):1985-1998 doi:10.1007/s13555-025-01457-4.

    PMID: 40542230
  4. 4

    Pyoderma gangrenosum.

    Maverakis E, Marzano AV, Le ST, et al.

    Nature reviews. Disease primers 2020; (6(1)):81 doi:10.1038/s41572-020-0213-x.

    PMID: 33033263
  5. 5

    The safety of treatments used in pyoderma gangrenosum.

    Feldman SR, Lacy FA, Huang WW

    Expert opinion on drug safety 2018; (17(1)):55-61 doi:10.1080/14740338.2018.1396316.

    PMID: 29065721
  6. 6

    Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.

    Moltrasio C, Romagnuolo M, Tavoletti G, et al.

    Seminars in immunopathology 2025; (47(1)):38.

    PMID: 41128863
  7. 7

    Peristomal Pyoderma Gangrenosum Responding to Risankizumab.

    Weigelt MA, Kirsner RS

    Advances in skin & wound care 2021; (34(6)):327-329 doi:10.1097/01.ASW.0000744324.59877.df.

    PMID: 33979822
  8. 8

    Case Report: Diagnostic difficulties, treatment, and association of the MEFV E148Q variant in a patient with PASH syndrome.

    Qin Q, Cao C, Liang J, et al.

    Frontiers in medicine 2025; (12()):1557540 doi:10.3389/fmed.2025.1557540.

    PMID: 40861239
  9. 9

    A complex case of PASH syndrome: pyoderma gangrenosum, acne, suppurative hidradenitis, and Crohn's disease in a 36-year-old smoker.

    Abdul Rahman N, Jazmati A, Roumi Jamal B, et al.

    Annals of medicine and surgery (2012) 2024; (86(10)):6280-6284 doi:10.1097/MS9.0000000000002533.

    PMID: 39359769
  10. 10

    [Severe acne in autoinflammatory diseases].

    Faleri S, Feichtner K, Ruzicka T

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2016; (67(11)):897-901 doi:10.1007/s00105-016-3840-0.

    PMID: 27448064
  11. 11

    Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.

    Sun NZ, Ro T, Jolly P, Sayed CJ

    The Journal of clinical and aesthetic dermatology 2017; (10(9)):36-38.

    PMID: 29344326
  12. 12

    Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.

    Nikolakis G, Kreibich K, Vaiopoulos A, et al.

    F1000Research 2021; (10()):381 doi:10.12688/f1000research.52100.2.

    PMID: 34540202
  13. 13

    Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?

    Wanzenberg A, Keshock E, Sami N

    Archives of dermatological research 2025; (317(1)):235 doi:10.1007/s00403-024-03689-4.

    PMID: 39804471
  14. 14

    A Unified Concept of Acne in the PAPA Spectrum Disorders.

    Maitrepierre F, Marzano AV, Lipsker D

    Dermatology (Basel, Switzerland) 2021; (237(5)):827-834 doi:10.1159/000509874.

    PMID: 32937626
  15. 15

    Difficult and rare forms of acne.

    Dessinioti C, Katsambas A

    Clinics in dermatology 2017; (35(2)):138-146 doi:10.1016/j.clindermatol.2016.10.005.

    PMID: 28274350
  16. 16

    Rapid Remission through Multimodal Therapy in a Severe Form of PASH Syndrome: A Case Report.

    Lohmer CB, von Stebut-Marx J, Wilhelm T, et al.

    Case reports in dermatology 2026; (18(1)):256-263 doi:10.1159/000551256.

    PMID: 42256375
  17. 17

    Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases.

    Tolkachjov SN, Fahy AS, Cerci FB, et al.

    Mayo Clinic proceedings 2016; (91(9)):1267-79.

    PMID: 27489052
  18. 18

    Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.

    May MR, Rübben A, Lennertz A, et al.

    Journal of personalized medicine 2022; (12(2)) doi:10.3390/jpm12020173.

    PMID: 35207660
  19. 19

    Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review.

    Shah M, Sachdeva M, Gefri A, Jfri A

    International journal of dermatology 2020; (59(2)):154-158 doi:10.1111/ijd.14637.

    PMID: 31512760

This page explains PASH syndrome treatment and monitoring for informational purposes only and is not medical advice. Your treating specialists should tailor medications, procedures, and monitoring to your situation.

Get notified when new evidence is published on PASH syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.